



Single-cell immunology of SARS-CoV-2 infection

Yuan Tian^{1,2}, Lindsay N. Carpp¹, Helen E. R. Miller¹, Michael Zager³, Evan W. Newell¹✉ and Raphael Gottardo^{1,2,4}✉

Gaining a better understanding of the immune cell subsets and molecular factors associated with protective or pathological immunity against severe acute respiratory syndrome coronavirus (SARS-CoV)-2 could aid the development of vaccines and therapeutics for coronavirus disease 2019 (COVID-19). Single-cell technologies, such as flow cytometry, mass cytometry, single-cell transcriptomics and single-cell multi-omic profiling, offer considerable promise in dissecting the heterogeneity of immune responses among individual cells and uncovering the molecular mechanisms of COVID-19 pathogenesis. Single-cell immune-profiling studies reported to date have identified innate and adaptive immune cell subsets that correlate with COVID-19 disease severity, as well as immunological factors and pathways of potential relevance to the development of vaccines and treatments for COVID-19. For facilitation of integrative studies and meta-analyses into the immunology of SARS-CoV-2 infection, we provide standardized, download-ready versions of 21 published single-cell sequencing datasets (over 3.2 million cells in total) as well as an interactive visualization portal for data exploration.

High-throughput single-cell technologies such as flow cytometry and mass cytometry, which can measure features on millions of individual cells, and high-dimensional single-cell technologies such as single-cell RNA sequencing (scRNA-seq), which can measure potentially thousands of features in individual cells, are well suited to support studies of the heterogeneity of immune responses and of how immune cells interact with other host cells and with pathogens. Specific applications of single-cell technologies in the field of immunology include identifying host immunological correlates of disease severity (potentially aiding the design of effective vaccines and therapeutics as well as the monitoring of each person's response to these approaches), elucidating molecular mechanisms of disease and enabling the identification of predictive biomarkers of disease outcome.

The ongoing COVID-19 pandemic has been described as 'an explosive pandemic of historic proportions' (ref. ¹), with over 250 million confirmed cases and over 5 million confirmed deaths worldwide². In addition to basic measures such as physical distancing and mask wearing, optimal management of the pandemic may involve a diverse armamentarium of scientific tools including effective and safe preventative vaccines³, early therapeutic interventions that can blunt progression to severe disease^{4,5} and anti-inflammatory treatments to counteract the harmful 'cytokine storm' in patients with severe disease^{6–8}. Toward the development of these tools, there is an urgent need to understand SARS-CoV-2 interactions with host cells and the host immune response⁹.

Here we provide an overview of the single-cell technologies that have been applied to COVID-19 studies and list the pertinent experimental aspects of each study (including sample size, technology platform and patient characteristics). We describe our efforts to organize and curate available single-cell sequencing datasets into an easily downloadable format, providing information on how to access these datasets. We also review key insights obtained from single-cell immune profiling and discuss opportunities and challenges of integrative analysis of publicly available datasets.

Single-cell technologies and available datasets

Single-cell technologies that have been used in COVID-19 studies to date are summarized in Table 1. They include 62 published articles and two preprint articles describing studies that applied one or more single-cell technologies in the context of COVID-19. Figure 1 displays the sample size and dimensionality of the studies; Supplementary Table 1 presents relevant experimental details and locations of publicly available datasets (raw FCS files are publicly available for six flow cytometry and three mass cytometry datasets, and 24 single-cell sequencing datasets are publicly available). Whereas flow cytometry is the most used technology in these studies, scRNA-seq and single-cell multi-omic profiling are also increasingly being used. Flow or mass cytometry studies analyzed data from up to ~300 individuals and up to 62 markers with one or multiple panels; 25 of the 54 datasets include longitudinal data (Fig. 1a). Most single-cell sequencing studies analyzed >50,000 cells from fewer than 150 individuals; only a few of them included longitudinal data (Fig. 1b).

In the following text, we briefly summarize key conclusions from the 64 studies shown in Fig. 1, focusing on the insights obtained via single-cell technologies, including studies still at the preprint stage or that have relatively small sample sizes. As most studies were performed in peripheral blood mononuclear cells (PBMCs), only limited conclusions can be drawn about the respiratory tract, the primary site of infection. Most studies focused on transcriptional (as opposed to protein or epigenetic) readouts. In the sections below, we summarize these findings in the context of innate immune cells, B cells and T cells, finally summarizing how these single-cell data may correlate with immune protection.

Innate immune responses

Most flow and mass cytometry-based studies of COVID-19 that analyzed PBMCs from patients with COVID-19 report reduced frequencies or abundances of circulating basophils^{10–12}, monocytes^{13–15} (especially CD14^{lo}CD16^{hi} non-classical monocytes¹⁶), dendritic cells (DCs)^{10,14,15,17} and natural killer (NK) cells^{14,15,17–19} when compared with those from healthy donors, with greater reductions in

¹Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ²Translational Data Science Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ³Center for Data Visualization, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ⁴Biomedical Data Sciences, Lausanne University Hospital, Lausanne, Switzerland. ✉e-mail: enewell@fredhutch.org; raphael.gottardo@chuv.ch

Table 1 | Summary of single-cell technologies that have been applied to study COVID-19

| Technology | Measurement | Methodology | Capacity | Pros and cons | Number of published or preprint COVID-19 articles ^a |
|-----------------------------|---|---|--|--|--|
| Flow cytometry ^b | Protein expression | Fluorophore-conjugated antibodies; cells are sorted into liquid droplets individually and flowed through a laser beam; the light emitted by each cell informs about marker expression | High throughput (millions of cells); up to ~30 markers | Pros: determination of immune cell subsets by well-defined surface markers and antibody panels; cells can be sorted for further analysis Cons: broad emission spectra of fluorophores | 47 |
| Mass cytometry (CyTOF) | Protein expression | Antibodies conjugated to heavy-metal isotopes; cells are nebulized, and the metal-conjugated antibodies are ionized; signals are detected by a time-of-flight mass spectrometer | High throughput (up to millions of cells); many-dimensional (>40 cellular parameters per cell) | Pros: avoids spectral overlap between fluorophores Cons: slower flow rate than flow cytometry; expensive; destructive (not possible to sort cells for further analysis) | 7 |
| scRNA-seq | Gene expression | Single cells are isolated (for example, through microfluidics, droplet-based methods or flow cytometry-based sorting) and lysed, and their transcripts are captured; the subsequent workflow is similar to that of bulk RNA-seq | High dimensional (>10,000 features measured per cell) | Pros: comprehensive and unbiased sequencing | 22 |
| CITE-seq ^c | Simultaneous surface protein expression and gene expression | Barcoded, oligonucleotide-conjugated antibodies label single cells that are analyzed by scRNA-seq | High dimensional (>100 proteins can be measured per cell in addition to >10,000 genes) | Pros: gene expression integrated with multi-omic profiling | 4 |
| scBCR/TCR-seq ^d | Immune antigen receptor repertoire | Single-cell VDJ-enriched libraries are generated using microfluidics, 5' molecular barcoding and constant region-specific primers | Paired, full-length receptor sequences from T cells and/or B cells including isotypes | Pros: comprehensive and unbiased sequencing; combination with multi-omic profiling possible (gene and protein expression) | 13 |

scBCR/TCR-seq, scBCR-seq and/or scTCR-seq. ^cCITE-seq includes scRNA-seq as part of the workflow; to omit redundancy, we did not count the CITE-seq studies in the scRNA-seq row. ^dIncludes spectral flow cytometry (one study), which is based on conventional flow cytometry but uses different optics and detectors. ^escBCR/TCR-seq can also be multi-omic; here we include 12 multi-omic studies that incorporated scBCR/TCR-seq and one scBCR-seq study.

individuals with severe COVID-19 than in those with mild COVID-19 (refs. ^{15–19}). Conversely, patients with COVID-19 have shown increased frequencies or abundances of circulating neutrophils, eosinophils and monocytic myeloid-derived suppressor cells compared with healthy donors, with greater increases in individuals with severe COVID-19 than in those with mild COVID-19 (refs. ^{11,14,16,17,19}). The neutrophil-to-lymphocyte ratio was also reported to be associated with severe COVID-19 (ref. ¹⁷).

NK cells. High-dimensional flow cytometry has enabled in-depth characterization of immune cell subsets. A report featuring a 28-color NK-cell-oriented panel described fewer circulating (yet more highly activated and proliferating) NK cells in patients with COVID-19 than in healthy controls¹⁸. Worse clinical outcomes were also correlated with increased levels of circulating adaptive NK cells (NKG2C⁺CD57⁺CD56^{dim}) and higher levels of perforin expression in CD56^{bright} NK cells¹⁸, implicating adaptive and activated NK cells in COVID-19 pathogenesis.

The above study is of particular notice because it incorporated an analysis of publicly available scRNA-seq data (NK cells in bronchoalveolar lavage fluid (BALF) from patients with COVID-19 (ref. ²⁰)). The data reveal high activation of NK cells in COVID-19 and corroborate results from flow cytometry¹⁸.

Neutrophils. Neutrophil extracellular traps have been implicated in severe COVID-19 (refs. ^{21,22}). A 'developing neutrophil' subpopulation, specifically increased in patients with acute respiratory distress syndrome, was identified through scRNA-seq and featured expression of neutrophil granule-related genes and a lack of expression of canonical neutrophil markers¹⁵.

Another study featuring scRNA-seq, high-dimensional flow cytometry and mass cytometry reported that severe COVID-19 was associated with a substantial increase in circulating immature neutrophils and the presence of a neutrophil cluster characterized by upregulated *S100A8* and *S100A9* (calprotectin) among other genes¹⁶.

DCs. One study²³ is notable due to its relatively large sample size ($n=52$ patients with COVID-19 and $n=62$ healthy controls) and its use of a phospho-specific cytometry by time of flight (CyTOF) panel to immunophenotype PBMCs along with cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) to profile gene and protein expression in DC-enriched PBMC samples from patients with COVID-19. One major observation from this study is the decrease in the frequency of plasmacytoid DCs (pDCs) in patients with COVID-19 and that expression of mammalian target of rapamycin (mTOR) signaling proteins was reduced in these




Fig. 1 | Visual representation of characteristics of the 64 published articles or publicly posted preprints on COVID-19 that have used one or more single-cell technologies (March 2020–March 2021). **a, b.** Scatterplots showing the number of participants versus the number of flow cytometry markers (**a**) or the number of cells for which data are available in each study (**b**). Each symbol represents a dataset using one of the single-cell technologies from a single study. Opacity indicates dataset availability to the public (light, no; dark, yes); shape indicates whether the dataset has longitudinal data (circle, no; triangle, yes); and color indicates assay type (red, flow cytometry; cyan, mass cytometry (**a**); red, repertoires; gold, RNA; green, RNA and protein; blue, RNA, protein and repertoires; magenta, RNA and repertoires (**b**)).

pDCs, suggesting that pDCs may have deficient interferon (IFN)- α signaling in patients with COVID-19.

Monocytes. In another study also distinguished by a relatively large sample size ($n=53$ patients with COVID-19, $n=8$ patients with flu-like illness and $n=48$ controls over two independent cohorts), researchers used single-cell transcriptomic (scRNA-seq) and proteomic (CyTOF) interrogation²⁴ to test whether distinct innate immune responses are associated with the clinical course of COVID-19. The study revealed that, compared with healthy controls, patients with mild COVID-19 had increased levels of inflammatory HLA-DR^{hi}CD11c^{hi}CD14⁺ monocytes. Conversely, patients with severe COVID-19 were distinguished not only by monocyte populations with low expression of HLA-DR (indicative of monocyte dysfunction²⁵) and enhanced expression of genes related to anti-inflammatory macrophage functions (such as *SELL* (*CD62L*) and *CD163*) but also by an abundance of immature neutrophils (including pro- and pre-neutrophils) expressing markers indicative of immunosuppression or dysfunction. These findings identify a dysfunctional monocyte response as well as dysregulated myelopoiesis as potentially important processes underlying the development of severe disease.

As discussed below, immune cell phenotyping via single-cell technologies has yielded potential insights into the immune pathways that may be dysregulated in severe COVID-19 (notably COVID-19-associated cytokine storm²⁶) and in multisystem inflammatory syndrome (MIS-C) associated with SARS-CoV-2 infection. These insights could in turn inform ongoing and future development of anti-inflammatory treatment strategies for COVID-19 by targeting immunological factors with therapeutic potential. Evidence that such anti-inflammatory treatment strategies may be effective is provided by the encouraging preliminary results of the RECOVERY trial of dexamethasone in patients who were hospitalized with COVID-19 (ref. 27) (which caused ongoing corticosteroid trials^{28–30} to stop early based on data and safety monitoring board recommendations), along with the results of meta-analyses of randomized clinical trials of corticosteroids in patients with severe COVID-19 (refs. 31,32). Moreover, flow cytometry, mass cytometry and scRNA-seq have all demonstrated reduced HLA-DR and CD86 expression on

monocytes in patients with severe COVID-19 (refs. 16,23,33) as well as in children with MIS-C associated with SARS-CoV-2 infection³⁴, implying potentially impaired antigen presentation to T cells. Downregulation of HLA-DR on monocytes could potentially be driven by interleukin (IL)-6, which has been shown to be elevated in patients with severe COVID-19 (refs. 10,19,35,36) and in pediatric patients with MIS-C^{34,37}, as decreased HLA-DR expression can be partially restored by tocilizumab³³ (a humanized immunoglobulin (Ig)G1 κ monoclonal antibody that targets IL-6 receptor (IL-6R) and blocks IL-6 signaling³⁸).

Tocilizumab has no efficacy in preventing disease progression³⁹ or intubation or death in hospitalized patients with moderate COVID-19 (ref. 40); however, the latter study⁴⁰ had wide confidence intervals in efficacy comparisons, and another report⁴¹ suggested potential benefit of tocilizumab in reducing the need for ventilation and mortality. Thus, the question of whether IL-6R blockade can benefit patients with moderate or severe COVID-19 disease remains open⁴¹, and other chemokine receptor blockers are also being tested in ongoing clinical trials^{42,43}. Additional applications of single-cell technologies in this context yielded the identification of the chemokine receptor CCR1 (refs. 11,44) as a potential therapeutic target based on scRNA-seq of nasopharyngeal samples from patients with critical or non-critical COVID-19 (ref. 44) or of nasopharyngeal and bronchial samples from patients with moderate or critical COVID-19 (ref. 11).

Macrophages. Multiple single-cell studies^{11,20,44,45} of airway and alveolar cells have also yielded insights into the role of macrophages in COVID-19, specifically that a dysregulated macrophage response may drive pathological inflammation⁴⁶. Patients with critical COVID-19 have manifested increased ligand–receptor interactions between epithelial cells and immune cells, upregulation of pro-inflammatory chemokine and cytokine genes in non-resident macrophages and *CCR1* upregulation in neutrophils, macrophages and CD8⁺ T cells¹¹. These findings suggest the influence of cycles of recruitment of immune cells to the lung (monocytes that differentiate into inflammatory macrophages, further recruitment and activation of more immune cells) on the epithelial damage observed in severe COVID-19. scRNA-seq analysis of cells in BALF has revealed

Box 1 | Organization and curation of single-cell sequencing datasets

With the aim of facilitating integrative analyses and meta-analyses, we have organized, curated and standardized a set of publicly available single-cell transcriptomic datasets. Of the 22 scRNA-seq and four CITE-seq studies in Table 1, openly accessible and downloadable FASTQ, count matrix, Seurat object or H5AD data are available for 23 studies. Of these 23 studies, we excluded ref.¹³, as only raw sequence reads were available, and ref.¹²⁷, as only four cell populations (monocytes, B cells, megakaryocytes and cell precursors) were available. Thus, our analysis processed 21 datasets. We first downloaded the datasets from repositories such as the Gene Expression Omnibus, ArrayExpress and the Genome Sequence Archive. The vast majority of scRNA-seq and CITE-seq studies (22 of 26) used the Seurat package^{126,128} for data analysis, whereas three studies used Scanpy¹²⁹ and one study used Pagoda2 (ref.¹³⁰). Thus, for simplicity, we prepared the datasets as Seurat objects in R and performed quality control, normalization, dimensionality reduction, clustering and cell type annotation using Seurat version 4. Seurat version 4 multimodal CITE-seq reference mapping enables not only more accurate resolution of granular cell types that are difficult to distinguish by transcriptomic data alone but also imputation of the expression of over two hundred surface proteins¹²⁶. We collected single-cell sequencing data of over 3.2 million single cells across 21 datasets^{11,15,16,20,23,24,44,45,47,48,100,101,106,120,131–137} and mapped each cell to the human PBMC CITE-seq reference¹²⁶.

As shown in Fig. 2a, substantial diversity was observed with respect to age, and there were more male patients with moderate or severe COVID-19 than female patients. Additionally, most samples were blood as opposed to another tissue type, such as from the airways (Fig. 2b). As only cell types in the Seurat version 4 multimodal CITE-seq PBMC reference set can be correctly mapped, for visualization purposes, we took only PBMC and whole-blood datasets (16 in total, the latter without neutrophils or basophils) and created a ‘merged dataset’ consisting of >2.5 million cells (we note that, as additional references and/or integration methods become available, other tissues could potentially be integrated as well). Figure 2c presents a visual representation of all cells in the merged dataset in the same uniform manifold approximation and projection (UMAP) space, along with standardized cell type annotations at three levels of granularity.

that the proportion of bronchoalveolar macrophages and the levels of inflammatory cytokine and chemokine receptors are positively associated with disease severity²⁰. Macrophages in severe COVID-19 were also distinguished by high expression of *FCN1* (encoding a member of the complement cascade) and *SPPI1* (encoding a pro-inflammatory cytokine), suggesting that alveolar macrophages may drive local inflammation in patients with severe COVID-19 (ref.²⁰). Finally, flow cytometry and scRNA-seq data of cells in BALF from patients with pneumonia caused by SARS-CoV-2 infection suggest that high levels of monocytes, as well as CD4⁺ and CD8⁺ T cells, are found in the alveolar space⁴⁵. scRNA-seq identified multiple clusters corresponding to tissue-resident alveolar macrophages and monocyte-derived alveolar macrophages, along with expression of *IFNG* in T cells from patients with pneumonia caused by SARS-CoV-2 infection. The identification of an IFN response signature by bulk sequencing of flow cytometry-sorted alveolar macrophages and the finding of SARS-CoV-2 RNA in alveolar macrophages (which suggests that SARS-CoV-2 can replicate in alveolar macrophages) gives strength to the hypothesis that activated T cells in severe COVID-19 release IFN- γ . In turn, this IFN- γ drives an IFN response in alveolar macrophages that leads to the recruitment

We also include standardized cell metadata (for example, disease severity and time points) from original publications when available. Briefly, the standardized disease severity categories are based on information provided in datasets and supplementary materials and defined as mild (not hospitalized), moderate (hospitalized (no ICU)) and severe (ICU). Standardized time points are defined as the number of days between symptom onset and the sampling time, if provided, and were estimated for patients when this information was not provided (see more details in the Supplementary Note).

To illustrate the usage of the merged dataset, Fig. 2d shows the frequencies of CD4⁺ T cells, CD8⁺ T cells, MAIT cells, CD56^{bright} NK cells, CD16⁺ monocytes and CD14⁺ monocytes in samples across 12 datasets grouped by disease severity and time points for COVID-19 samples based on the standardized metadata. Consistent with published results^{17,33,57,83,84,90,138,139}, reductions in numbers of CD4⁺ T cells, CD8⁺ T cells, MAIT cells and CD56^{bright} NK cells were each associated with COVID-19 severity. When sampled at an early or intermediate stage of the clinical course, we also observed decreased CD16⁺ monocyte numbers in patients with severe versus mild COVID-19 (Fig. 2d), which is consistent with published results^{16,24}. Conversely, an increase in CD14⁺ monocyte numbers was observed in patients with severe versus mild COVID-19, regardless of when the samples were obtained in the clinical course (Fig. 2d). To facilitate standardization and sharing of future datasets by the community, the code used to process datasets is available at GitHub (https://github.com/RGLab/covid19_sc).

Furthermore, we provide interactive visualization of these datasets on a visualization portal (<https://atlas.fredhutch.org/fredhutch/covid>). Figure 3 shows an example screenshot of the visualization portal. The processed Seurat objects can be easily downloaded from the visualization portal; to ensure that our resource remains maximally relevant to the research community, we encourage users to request datasets to be added to the portal as new studies emerge. We plan to update the portal as needed to ensure that it includes highly requested studies. We hope that the standardized datasets we present here will facilitate reanalyses and meta-analyses and accelerate much-needed translational discoveries to help stem the COVID-19 crisis.

of monocyte-derived alveolar macrophages, completing an ‘inflammatory signaling loop’ (ref.⁴⁵).

An alternative RNA-seq analysis of PBMCs from four healthy donors, five patients with influenza infection and eight patients with COVID-19 reported that classical monocytes in those with severe COVID-19 are distinguished by an IFN type I (IFN-I)-related transcriptional signature and an IL-1 β -related inflammatory transcriptional signature⁴⁷. This finding generated the hypothesis that the IFN-I response contributes to detrimental inflammation in severe COVID-19. In a study with a much larger sample size (including 130 patients with COVID-19 from three different centers in the UK), scRNA-seq and quantification of 188 cell surface proteins⁴⁸ revealed a positive association between the frequency of proliferating monocytes and *MKI67*- and *TOP2A*-expressing DCs with COVID-19 disease severity. The same study also described how platelet expansion was associated with severe COVID-19, along with enhanced interactions of platelets with C1⁺CD16⁺ monocytes and CD16⁺ monocytes in COVID-19. These findings lend support to the role of both platelets and monocytes in the tissue thrombosis that has been reported in COVID-19 (ref.⁴⁹).

B cell responses

Neutralizing antibodies (nAbs) have been heavily implicated in protection against SARS-CoV-2 infection and COVID-19 disease^{50–54}, and thus intense interest has focused on identifying potent nAbs against SARS-CoV-2. Such analysis requires a single-cell approach, owing to the extensive variable (V), diversity (D) and joining (J) gene (VDJ) recombination and somatic hypermutation in B cells⁵⁵.

Immunoglobulin sequencing. A general strategy for identifying relevant antibody sequences has been to sort and process, via scRNA-seq, individual antigen-specific memory B cells (for example, specific to the receptor-binding domain (RBD) in the spike glycoprotein⁵⁶ or the spike trimer^{15,57–59}) from individuals convalescing from COVID-19. VDJ sequencing performed at the single-cell level (scVDJ-seq³⁴) has led to identification of nAbs with prophylactic or therapeutic efficacy against SARS-CoV-2, feeding into the robust pipeline of nAb clinical trials⁶⁰.

In a study that employed high-throughput scRNA-VDJ-seq, about 9,000 RBD-binding B cell clonotypes were identified, yielding 14 potent nAbs, one of which was shown to protect against SARS-CoV-2 in a mouse model⁵⁶. The coupled scRNA-seq data allowed the identification of naive and memory B cell subsets and helped improve the efficiency of nAb selection by filtering out clonotypes enriched in naive and exhausted B cells⁵⁶. A different study also using scRNA-VDJ-seq identified 19 potent nAbs, including RBD-binding and non-RBD-binding nAbs, one of which was shown to protect against SARS-CoV-2 in a hamster model⁶¹. The integration of two parallel workflows, both of which featured scRNA-seq and one of which incorporated single-cell functional assays, has been applied in combination with scVDJ-seq to identify five major classes of nAbs with different reactivities to the spike glycoprotein and cross-reactivity with SARS-CoV-2 (ref. ⁵⁴). A multi-omic integration of single-cell data, including scRNA-seq and CITE-seq, along with B cell receptor (BCR) and T cell receptor (TCR) sequencing, of PBMCs from patients with ‘stable’ COVID-19 (who were hospitalized and ultimately discharged) and patients with ‘progressive’ COVID-19 (who were treated in the intensive care unit (ICU) and ultimately succumbed to the disease) supported a complex B cell response in COVID-19, including a high proportion of unmutated I γ heavy chain (IGHG) B cell clones present alongside multiple mutated B cell clones that did not appear to increase levels of somatic hypermutation over time⁶². The latter could potentially be explained by memory B cell cross-reactivity with other coronaviruses or failed formation of robust germinal center reactions⁵⁹.

B cell markers. High-dimensional flow cytometry has been used to characterize and compare B cell responses in patients with different severities of COVID-19 disease. A 24-marker B-cell-focused panel designed to identify B cell populations, evaluate their activation status and assess homing potential⁶³ allowed the identification of a correlation between overactivation of extrafollicular B cells and COVID-19 disease severity, along with greater expansion of

antibody-secreting cells in severe versus milder disease. Patients with severe disease had high serum titers of RBD-targeting SARS-CoV-2 nAbs, raising the question of whether this distinct B cell response in patients with severe COVID-19 is ineffective or potentially even pathogenic. Other studies have described how the humoral immune response (as assessed by BCR clonal expansion and B cell activation) could be correlated with disease severity⁶⁴; however, it remains an open question whether these positive correlations are simply due to increased initial viral load. This is a particularly complex question, with studies reporting direct^{65–72}, inverse^{73,74} or no⁷⁵ correlation. These discrepant findings may be the result of differences in sampling compartment⁶⁸ (saliva, blood or anal), timing of sample collection and population differences. In any case, additional studies are warranted to define the cellular and molecular determinants that dictate protective versus non-protective humoral responses in infected individuals. The potential of antibody-dependent enhancement of COVID-19 disease must also be considered⁷⁶.

Convergent antibody clusters (antibodies with highly similar VDJs shared by multiple patients, which generally comprise only a small proportion of the virus-specific B cell response⁷⁷), have also been identified⁷⁸, with the suggestion that the majority of patients with COVID-19 have convergent Ig heavy chains against the RBD, which may bode well for spike-based or RBD-based vaccines.

B cell phenotypes. In a study⁷⁹ investigating longitudinal samples from individuals who had recovered from mildly symptomatic COVID-19, researchers used RBD tetramer enrichment and flow cytometry to phenotype the rare population of RBD-specific B cells. Numbers of RBD-specific memory B cells increased from 1 to 3 months after symptom onset and were substantially higher in COVID-19 samples than in healthy controls. Moreover, numbers of memory B cells displaying a Tbet^{hi}IgG⁺CD21⁺CD27⁺ phenotype (that is, a ‘classical’ memory B cell phenotype) also increased from 1 to 3 months after symptom onset, whereas levels of Tbet^{hi} memory B cells, which are typically found in chronic infections, remained low. The question of whether SARS-CoV-2-specific memory B cells can produce nAbs after reactivation by secondary infection has also been addressed: sorting and sequencing of RBD-specific single B cells and their BCRs suggested that memory B cells may help protect from secondary infections.

Human tissue-imaging platforms coupled with multi-color immunofluorescence and multispectral imaging via quantitative automated scanning microscopy have been used to study, at the single-cell level, thoracic lymph nodes and spleens obtained via from autopsies of patients who succumbed to COVID-19 (ref. ⁵⁹). Compared with single-cell approaches requiring dissociation of tissue, an advantage of this approach is that tissue architecture could be largely preserved, enabling study of cell–cell interactions. A loss of germinal centers in the lymph nodes of these patients, accompanied by substantial reductions in numbers of germinal center B cells and follicular helper T (T_{FH}) cells in the lymph nodes and spleens, was reported using this approach⁵⁹. As optimal germinal center


Fig. 2 | Visual representation of single-cell transcriptomic data. **a**, Plots showing the distribution of age (left) and sex (right) among individuals included in the collected 21 datasets. **b**, Bar plot showing the number of samples per tissue type among the collected 21 datasets. **c**, UMAP plots showing the projection of over 2.5 million single cells from 16 PBMC and whole-blood datasets (the latter without neutrophils or basophils) mapped to the Seurat CITE-seq reference and colored and labeled by reference-defined cell type annotations at level 1 (l1, left), level 2 (l2, middle) and level 3 (l3, right) granularity. CTL, cytotoxic T lymphocyte; eryth, erythrocyte; ILC, innate lymphoid cell; mono, monocyte; T_{reg}, regulatory T cell; ASDC, Axl⁺ dendritic cell; cDC, conventional dendritic cell; dnT, double-negative T cell; gdT, $\gamma\delta$ T cell; HSPC, hematopoietic stem and progenitor cell; mDC, myeloid dendritic cell; TCM, central memory T cell; TEM, effector memory T cell. **d**, Box plots showing the frequencies of CD4⁺ T cells, CD8⁺ T cells, MAIT cells, CD56^{bright} NK cells, CD16⁺ monocytes and CD14⁺ monocytes among samples grouped by disease severity and time points for COVID-19 samples. Samples from Arunachalam et al.²³ (enriched for DCs), Meckiff et al.¹⁰⁰ (enriched for antigen-specific CD4⁺ T cells), Kusnadi et al.¹⁰¹ (enriched for antigen-specific CD8⁺ T cells) and Bacher et al.¹⁰⁶ (enriched for antigen-specific CD4⁺ T cells) were excluded. Early, ≤ 8 d after symptom onset; intermediate, > 8 and ≤ 15 d after symptom onset; late, > 15 d after symptom onset. Statistical significance between mild and severe disease was determined by Wilcoxon test. * $P \leq 0.05$, ** $P \leq 0.01$, *** $P \leq 0.001$, **** $P \leq 0.0001$.

reactions are essential for the production of high-affinity antibodies⁸⁰, these results suggest that the increased proportions of plasmablasts observed in patients with COVID-19 (particularly in those with severe COVID-19)^{10,15,17,59} are a correlate of suboptimal antiviral humoral immunity and disease rather than protection. Other emerging single-cell imaging-based techniques, such as single-cell spatial transcriptomics, may be particularly relevant to the

emerging field of pathological studies in organs from individuals who succumbed to COVID-19 (refs. 81,82).

T cell responses

Multiple studies using flow cytometry of PBMCs from patients with COVID-19 have reported T lymphopenia: compared with the lower limit of normal or with levels observed in healthy controls,



substantially reduced T cell^{14,17,19,83–85}, CD4⁺ T cell^{17,57,58,83–85}, CD8⁺ T cell^{10,17,57,58,83–85}, CD8⁺ mucosal-associated invariant T (MAIT) cell¹⁷, $\gamma\delta$ T cell¹⁰, $\alpha\beta$ T cell (some subsets)¹⁰ and regulatory T cell⁸⁴ counts have been observed in patients with mild or severe COVID-19. Similar T cell lymphopenia has been observed in patients with COVID-19-associated MIS-C^{34,37,86,87}. While it has been reported¹³ that reductions in CD4⁺ and CD8⁺ T cell numbers were comparable between patients with COVID-19 and patients with influenza, some researchers have observed³³ that the reduction in CD4⁺ T cell numbers is greater in patients with COVID-19 than that in patients with influenza. Decreased T cell populations have also been associated with disease severity, as numbers of both CD4⁺ (refs. ^{57,84}) and CD8⁺ (ref. ⁵⁷) T cells were shown to be substantially reduced in patients with severe versus moderate or mild COVID-19 or in ICU versus non-ICU cases⁸³. An increased CD4⁺/CD8⁺ T cell ratio has also been reported in patients with COVID-19 (refs. ^{19,58}), suggesting that SARS-CoV-2 infection might preferentially impact CD8⁺ T cells.

T cell phenotype. Multiparametric flow cytometry has also revealed phenotypic and functional alterations in T cells of patients with COVID-19, with a general theme emerging of hyperactivation of T cells in COVID-19, as demonstrated by elevated subpopulations expressing activation, proliferation or exhaustion markers. Levels of activated (HLA-DR⁺CD38⁺ (refs. ^{10,14,17,58}), CD38⁺ (ref. ⁸⁸), HLA-DR⁺ (ref. ⁸⁹), CD25⁺CD4⁺ (ref. ¹⁰) and CD25⁺CD8⁺ (ref. ¹⁰)), proliferating (Ki67⁺CD8⁺ (refs. ^{58,88}) or Ki67⁺CD4⁺ (ref. ⁸⁸)) and exhausted (PD-1⁺CD8⁺ and/or PD-1⁺CD4⁺ (refs. ^{83,88}), TIGIT⁺ (ref. ⁸⁹) or NKG2A⁺ (ref. ⁹⁰)) T cells have been shown to dramatically increase in patients with COVID-19 or in patients with severe COVID-19 compared with healthy controls, and most activated (CD38⁺PD-1⁺) CD8⁺ T cells in patients with acute COVID-19 have been shown to be specific for SARS-CoV-2 (ref. ⁸⁸). However, perhaps due to differences in the timing of sampling, healthy controls, patients with influenza and patients with COVID-19 with similarly low abundances of HLA-DR⁺CD38⁺ activated CD8⁺ T cells have been described. Notably, scRNA-seq and single-cell TCR sequencing (scTCR-seq) analysis of CD8⁺ T cells in BALF samples identified signatures of tissue-resident memory T cells and increased levels of clonal expansion associated with mild disease, whereas elevated proliferative capacity was correlated with severe disease²⁰. scRNA-seq analysis of cerebrospinal fluid leukocytes isolated from patients with COVID-19 and neurological sequelae ('neuro-COVID') has uncovered high levels of CD4⁺ T cells expressing exhaustion markers (for example, *ICOS*, *HAVCR2* (*TIM3*) and *CD226*) compared with those in control patients.

Flow cytometry and scRNA-seq have also identified altered T cell differentiation and cytotoxicity in COVID-19. Patients with severe COVID-19 had higher proportions of circulating cytotoxic CD8⁺ T cells than healthy controls¹⁷, and CD8⁺ T cells in nasopharyngeal and bronchial samples from patients with severe COVID-19 have increased expression of cytotoxic molecules¹¹. This increased cytotoxicity has been proposed to contribute to epithelial damage¹¹. Regarding differentiation, a decrease in peripheral naive and central memory CD8⁺ T cells and an increase in senescent and effector memory CD45RA⁺CD8⁺ T cells in patients with COVID-19 (ref. ¹⁹) have been reported, suggesting a skew toward terminal differentiation. In another study³⁹, numbers of CD4⁺BCL-6⁺ germinal center type T_{FH} cells were substantially decreased in thoracic lymph node and spleen autopsy tissue from patients with COVID-19, accompanied by high levels of tumor necrosis factor (TNF)- α at the follicle and increased numbers of T helper type 1 (T_{H1}) cells. These findings suggest that COVID-19 impairs T_{FH} cell differentiation, which may explain the lack of germinal centers mentioned above.

T cell specificity. SARS-CoV-2-specific T cells recognizing both spike- and non-spike epitopes have been identified in patients with acute COVID-19 and in convalescent patients through various flow

cytometry-based techniques such as intracellular cytokine staining, activation-induced marker assays (including antigen-reactive T cell enrichment) and peptide-major histocompatibility complex (MHC) multimers (Supplementary Table 1), demonstrating the formation of virus-specific memory T cells after infection^{79,88,91–98}. Although patients with severe COVID-19 showed overall higher breadth and magnitude of SARS-CoV-2-specific T cell responses than patients with mild COVID-19, higher proportions of SARS-CoV-2-specific CD8⁺ T cells were observed in mild versus severe cases⁹⁷. SARS-CoV-2-specific CD4⁺ T cells are predominantly T_{H1} cells and largely display a central memory T phenotype, whereas SARS-CoV-2-specific CD8⁺ T cells are more enriched in effector memory and terminally differentiated effector subsets^{95,98,99}. scRNA-seq and scTCR-seq analysis of SARS-CoV-2-reactive CD4⁺ T cells revealed an association between increased SARS-CoV-2-specific cytotoxic CD4⁺ T cells and cytotoxic T_{FH} cells with disease severity and an inverse association of regulatory T cells with disease severity¹⁰⁰. SARS-CoV-2-reactive CD8⁺ T cells were shown to have enhanced expression of cytotoxic and inflammatory genes with higher levels of TCR clonal expansion in patients with severe disease, supporting an association of overactivated antigen-specific T cells with COVID-19 pathogenesis¹⁰¹. As in vitro stimulation can radically alter the gene expression profiles of reactive T cells, further studies using peptide-MHC multimers together with single-cell sequencing should provide complementary and additional insights into the phenotype and function of SARS-CoV-2-specific T cells. In addition, single-cell multi-omic technologies, such as single-cell sequencing assay for transposase-accessible chromatin (scATAC-seq), could be applied to investigate whether SARS-CoV-2-specific T cells retain epigenetic fingerprints that may dictate their recall responses.

Contribution of T cells to COVID-19 immunity. Many questions remain about how prior exposure to endemic coronaviruses and cross-reactive memory T cell immunity shape the immune response to SARS-CoV-2 (refs. ^{102,103}). Intracellular cytokine staining and flow cytometry, enzyme-linked immune absorbent spot (ELISpot) and FluoroSpot assays have been key single-cell technologies for detecting cross-reactive memory CD4⁺ T cells in SARS-CoV-2-unexposed individuals (ranging between approximately 20% and 50% of individuals tested across geographically diverse cohorts), whereas cross-reactive memory CD8⁺ T cells are much less common^{88,91–95,104}. It has been postulated that cross-reactive memory CD4⁺ T cells may provide protective immunity against SARS-CoV-2 infection and reduce disease severity by promoting B cell and antibody responses or by mediating rapid local antiviral immunity at sites of infection, including the lung and upper respiratory tract¹⁰³. However, it was reported¹⁰⁵ that pre-existing cross-reactive memory CD4⁺ T cells may not only have low TCR avidity with reduced clonal expansion but also exacerbate inflammation and disease severity, especially in the elderly¹⁰⁶. Thus, the roles of pre-existing cross-reactive memory T cells in SARS-CoV-2 infection and vaccination in the general population warrant further investigation.

Correlates of immune protection at the single-cell level

With the rapid growth of single-cell datasets on the immunology of COVID-19, one open question is how to best leverage current and emerging public datasets. Ongoing efficacy trials of candidate COVID-19 vaccines are generating single-cell immune-profiling datasets that could be applied to identifying correlates of risk and correlates of protection against primary and secondary endpoints in these trials, for instance, as we have done previously for the RV144 HIV vaccine efficacy trial¹⁰⁵. Because of limited specimen volumes in COVID-19 vaccine efficacy trials and the large number of immunological biomarkers that could potentially be evaluated as correlates, it will be critical to perform pilot studies to optimize and identify assays and associated immune signatures with favorable




Fig. 3 | An example screenshot of the visualization portal. The website provides visualization of 21 individual datasets and the merged dataset consisting of 16 datasets. The UMAP plot shows the merged dataset consisting of over 2.5 million cells mapped to the human PBMC CITE-seq reference¹²⁶. Processed datasets can also be downloaded from the website at <https://atlas.fredhutch.org/fredhutch/covid>. QC, quality control.

statistical properties for correlates analyses. Important factors in determining the best correlates include high reproducibility, large dynamic range in vaccine recipients and low response range (low false positive rate) at baseline in vaccine recipients and in placebo recipients after placebo treatment. To help expedite correlates analyses, existing single-cell datasets could be explored to optimize and identify highly reproducible single-cell immunological signatures, which will be useful in variable down-selection.

Another major application of these collated datasets is the potential for integrative analyses and meta-analyses, such as the recent meta-analysis of 107 lung scRNA-seq studies that identified additional proteases that may potentially be involved in SARS-CoV-2 infection¹⁰⁷.

Box 1 (together with Figs. 2 and 3) illustrates one way to organize publicly available single-cell data for use in integrative analyses. Readers should note, however, that a search for biomarkers and

signatures associated with COVID-19 disease severity or progression using such published data faces several challenges.

One challenge is whether and how to account for trial-participant demographics, as ethnic^{108–111}, sex^{110,112} and age^{113–117} differences in clinical presentation, immune responses and outcomes of SARS-CoV-2 infection have been identified, even when adjusting for potential confounders. A second major challenge is the substantial heterogeneity thus far in the ordinal scales that have been used for assessing coronavirus disease severity¹¹⁸: of the 44 studies that categorized disease severity, 7 used World Health Organization scores, 5 used National Health Commission of China guidelines, 3 used National Institutes of Health (NIH) scores, 1 used German Robert Koch Institute symptom classification, 1 used National Early Warning Score, 4 did not provide relevant information on how disease severity was defined, and 23 used custom scoring (Supplementary Table 1). Moreover, for studies that obtained samples at 'early' and 'late' disease stages, there is substantial heterogeneity in how the time after symptom onset is defined. The incorporation of standardized definitions of disease severity into future single-cell immune-profiling studies would facilitate such integrative and meta-analyses. As one approach to overcome this problem, seven disease severity categories have been defined¹¹⁹ and manually assigned standardized categories in an integrated analysis of 4,780 PBMC transcriptomic samples from patients infected with a different virus (16 in total across 26 datasets), an approach that may help mitigate the problem caused by non-standardized definitions of disease severity. Integrative analysis of bulk sequencing data has supported the hypothesis that there is a conserved pan-viral response associated with disease severity: in an integrative analysis¹²⁰ of three single-cell datasets (two CITE-seq datasets^{23,120} and one scRNA-seq dataset¹⁵; 264,224 cells from 71 PBMC samples overall) from three independent cohorts including healthy controls^{15,23,120}, patients with SARS-CoV-2 infection^{15,23,120} and patients with influenza or respiratory syncytial virus infection²³ reported a 'meta-virus signature' score in single myeloid cells that was positively correlated with viral infection severity across different virus strains.

The lack of standardized experimental protocols and analysis pipelines is an additional challenge in integrating single-cell datasets. As a result, published results and datasets can be difficult to compare and integrate due to experimental and computational variation on how the cells and datasets were processed. Fortunately, the research community has worked hard to provide computational approaches that can be used to reduce technical variation and produce standardized cell annotations that can be compared, visualized and modeled across datasets^{121,122}. These approaches have already been used in many of the COVID-19 single-cell studies published to date to correct for batch effects¹²⁰. Those part of the Human Cell Atlas¹²³ initiative have also been working to standardize the different aspects of single-cell sequencing, and the Human Cell Atlas Data Portal provides publicly available datasets processed by standardized pipelines¹²⁴.

Conclusions

Single-cell analyses have held up to their promise of overcoming certain limitations of bulk methods and enabling a deep dive into the cellular heterogeneity of antiviral immune responses. Multiple single-cell immune-profiling studies of patients with COVID-19 have identified distinct cell subsets of the innate and adaptive immune systems that correlate with disease severity; this body of evidence supports the hypothesis that such subsets may have important functions in blunting (or even enhancing) COVID-19 disease severity. There is also evidence to suggest that targeting certain immunological factors such as cytokine or chemokine receptors (for example, IL-6R and CCR1) might curb pathogenic responses and improve protective immunity. In the near-term future, studies applying single-cell multi-omic technologies such as CITE-seq and single-cell B cell receptor sequencing (scBCR-seq) or scTCR-seq

with peptide–MHC multimers are needed to further characterize the phenotypes and functions of immune cell subsets implicated in COVID-19 protection and of those implicated in progression. Application of multi-omic technologies such as scATAC-seq to understand the epigenetic changes associated with SARS-CoV-2 infection in immune cells, especially in antigen-specific T and B cells, may help identify new avenues to pursue for COVID-19 therapies. Moreover, additional multi-omic spatial immune-profiling studies are needed to further dissect local immune responses against SARS-CoV-2 in infected tissues such as the lung. In the longer term, single-cell immune-profiling studies with sufficiently large sample sizes and participant diversity will be valuable to help investigate potential sex-related and age-related differences in COVID-19, including whether the immune cell subsets of interest described above vary in frequency or in function in a sex-dependent manner. Application of single-cell immune profiling to better understand the mechanisms driving the range of post-COVID-19 conditions (most prominently, long COVID) is also a relatively underexplored area with many unanswered questions.

The scientific community has mobilized in unprecedented fashion in response to the ongoing COVID-19 pandemic. Large collaborative efforts such as the US NIH-funded Immunophenotyping Assessment in a COVID-19 Cohort study (NCT04378777) and the COVID-19 Cell Atlas¹²⁵ (Wellcome Sanger Institute–Chan Zuckerberg Initiative), to name a few, are generating freely available, open-access datasets at the single-cell level, and work is being done to standardize protocols and metadata as well. These datasets have been derived from patients with COVID-19 of varying severity and include different tissues, cohort features and time points. Looking ahead, we anticipate that the amount and complexity of single-cell datasets will rapidly grow, including in important populations, such as pediatric patients (for whom little single-cell data currently exists) and that reanalyses and meta-analyses will become more common as standards become available.

Received: 24 November 2020; Accepted: 15 October 2021;
Published online: 20 December 2021

References

- Joszt, L. Fauci and panel discuss ongoing challenges of the COVID-19 pandemic, and lessons learned. *AJMC* (19 October 2021); <https://www.ajmc.com/view/fauci-and-panel-discuss-ongoing-challenges-of-the-covid-19-pandemic-and-lessons-learned>
- Coronavirus Disease (COVID-19) Pandemic (WHO, 2021); <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>
- Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. *Nat. Rev. Immunol.* **21**, 73–82 (2021).
- Kim, P. S., Read, S. W. & Fauci, A. S. Therapy for early COVID-19: a critical need. *JAMA* **324**, 2149–2150 (2020).
- Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. *N. Engl. J. Med.* **384**, 238–251 (2021).
- Prescott, H. C. & Rice, T. W. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. *JAMA* **324**, 1292–1295 (2020).
- Zhang, Y., Chen, Y. & Meng, Z. Immunomodulation for severe COVID-19 pneumonia: the state of the art. *Front. Immunol.* **11**, 577442 (2020).
- Lariccia, V. et al. Challenges and opportunities from targeting inflammatory responses to SARS-CoV-2 infection: a narrative review. *J. Clin. Med.* **9**, 4021 (2020).
- Grifoni, A. et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. *Cell Host Microbe* **27**, 671–680 (2020).
- Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. *Nat. Med.* **26**, 1623–1635 (2020).
- Chua, R. L. et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. *Nat. Biotechnol.* **38**, 970–979 (2020).
- Rodriguez, L. et al. Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. *Cell Rep. Med.* **1**, 100078 (2020).
- Mudd, P. A. et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. *Sci. Adv.* **6**, eabe3024 (2020).

14. Zhou, R. et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. *Immunity* **53**, 864–877 (2020).
15. Wilk, A. J. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat. Med.* **26**, 1070–1076 (2020).
16. Silvin, A. et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. *Cell* **182**, 1401–1418 (2020).
17. Kuri-Cervantes, L. et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. *Sci. Immunol.* **5**, eabd7114 (2020).
18. Maucourant, C. et al. Natural killer cell immunotypes related to COVID-19 disease severity. *Sci. Immunol.* **5**, eabd6832 (2020).
19. Mazzoni, A. et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. *J. Clin. Invest.* **130**, 4694–4703 (2020).
20. Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nat. Med.* **26**, 842–844 (2020).
21. Barnes, B. J. et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. *J. Exp. Med.* **217**, e20200652 (2020).
22. Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. *JCI Insight* **5**, e138999 (2020).
23. Arunachalam, P. S. et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. *Science* **369**, 1210–1220 (2020).
24. Schulte-Schrepping, J. et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. *Cell* **182**, 1419–1440 (2020).
25. Venet, F., Demaret, J., Gossez, M. & Monneret, G. Myeloid cells in sepsis-acquired immunodeficiency. *Ann. NY Acad. Sci.* **1499**, 3–17 (2020).
26. Fajgenbaum, D. C. & June, C. H. Cytokine storm. *N. Engl. J. Med.* **383**, 2255–2273 (2020).
27. RECOVERY Collaborative Group et al. Dexamethasone in hospitalized patients with COVID-19—preliminary report. *N. Engl. J. Med.* **384**, 693–704 (2020).
28. Dequin, P. F. et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. *JAMA* **324**, 1298–1306 (2020).
29. Tomazini, B. M. et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. *JAMA* **324**, 1307–1316 (2020).
30. Angus, D. C. et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. *JAMA* **324**, 1317–1329 (2020).
31. Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *JAMA* **324**, 1330–1341 (2020).
32. Siemieniuk, R. A. et al. Drug treatments for COVID-19: living systematic review and network meta-analysis. *BMJ* **370**, m2980 (2020).
33. Giamarellos-Bourboulis, E. J. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host Microbe* **27**, 992–1000 (2020).
34. Carter, M. J. et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nat. Med.* **26**, 1701–1707 (2020).
35. Zhou, Y. et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. *Natl Sci. Rev.* **7**, 998–1002 (2020).
36. Mann, E. R. et al. Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. *Sci. Immunol.* **5**, eabd6197 (2020).
37. Gruber, C. N. et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). *Cell* **183**, 982–995 (2020).
38. Hennigan, S. & Kavanaugh, A. Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. *Ther. Clin. Risk Manag.* **4**, 767–775 (2008).
39. Salvarani, C. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. *JAMA Intern. Med.* **181**, 24–31 (2021).
40. Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. *N. Engl. J. Med.* **383**, 2333–2344 (2020).
41. Huang, E. & Jordan, S. C. Tocilizumab for COVID-19—the ongoing search for effective therapies. *N. Engl. J. Med.* **383**, 2387–2388 (2020).
42. *Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients* (ClinicalTrials.gov, 2020); <https://clinicaltrials.gov/ct2/show/NCT04500418>
43. *Maraviroc in Patients With Moderate and Severe COVID-19* (ClinicalTrials.gov, 2021); <https://clinicaltrials.gov/ct2/show/NCT04435522>
44. Trump, S. et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. *Nat. Biotechnol.* **39**, 705–716 (2020).
45. Grant, R. A. et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. *Nature* **590**, 635–641 (2021).
46. Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat. Rev. Immunol.* **20**, 355–362 (2020).
47. Lee, J. S. et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. *Sci. Immunol.* **5**, eabd1554 (2020).
48. Stephenson, E. et al. Single-cell multi-omics analysis of the immune response in COVID-19. *Nat. Med.* **27**, 904–916 (2021).
49. Levi, M., Thachil, J., Iba, T. & Levy, J. H. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematol.* **7**, e438–e440 (2020).
50. Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate. *J. Clin. Microbiol.* **58**, e02107-20 (2020).
51. Klasse, P. J. & Moore, J. P. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. *eLife* **9**, e57877 (2020).
52. Alsoussi, W. B. et al. A potentially neutralizing antibody protects mice against SARS-CoV-2 infection. *J. Immunol.* **205**, 915–922 (2020).
53. Kreye, J. et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. *Cell* **183**, 1058–1069 (2020).
54. Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature* **584**, 443–449 (2020).
55. Bassing, C. H., Swat, W. & Alt, F. W. The mechanism and regulation of chromosomal V(D)J recombination. *Cell* **109**, S45–S55 (2002).
56. Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. *Cell* **182**, 73–84 (2020).
57. Wang, F. et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J. Infect. Dis.* **221**, 1762–1769 (2020).
58. Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science* **369**, eabc8511 (2020).
59. Kaneko, N. et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. *Cell* **183**, 143–157 (2020).
60. Renn, A., Fu, Y., Hu, X., Hall, M. D. & Simeonov, A. Fruitful neutralizing antibody pipeline brings hope to defeat SARS-CoV-2. *Trends Pharmacol. Sci.* **41**, 815–829 (2020).
61. Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature* **584**, 450–456 (2020).
62. Unterman, A. et al. Single-cell omics reveals dysynchrony of the innate and adaptive immune system in progressive COVID-19. Preprint at *medRxiv* <https://doi.org/10.1101/2020.07.16.20153437> (2020).
63. Woodruff, M. C. et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. *Nat. Immunol.* **21**, 1506–1516 (2020).
64. Zhang, F. et al. Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. *Signal Transduct. Target. Ther.* **5**, 156 (2020).
65. Wang, Y. et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. *J. Clin. Invest.* **130**, 5235–5244 (2020).
66. Chen, W. L. et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerg. Microbes Infect.* **9**, 469–473 (2020).
67. Zheng, S. F. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. *BMJ* **369**, m1443 (2020).
68. Silva, J. et al. Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. Preprint at *medRxiv* <https://doi.org/10.1101/2021.01.04.21249236v1> (2021).
69. Pujadas, E. et al. SARS-CoV-2 viral load predicts COVID-19 mortality. *Lancet Respir. Med.* **8**, e70 (2020).
70. Liu, Y. et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect. Dis.* **20**, 656–657 (2020).
71. Fajnzylber, J. et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. *Nat. Commun.* **11**, 5493 (2020).
72. Maltezou, H. C. et al. Association between upper respiratory tract viral load, comorbidities, disease severity and outcome of patients with SARS-CoV-2 infection. *J. Infect. Dis.* **223**, 1132–1138 (2021).
73. Argyropoulos, K. V. et al. Association of initial viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms. *Am. J. Pathol.* **190**, 1881–1887 (2020).
74. Hasanoglu, I. et al. Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg. *Infection* **49**, 117–126 (2021).
75. Lee, S. et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. *JAMA Intern. Med.* **180**, 1447–1452 (2020).
76. Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat. Microbiol.* **5**, 1185–1191 (2020).
77. Davis, C. W. et al. Longitudinal analysis of the human B cell response to Ebola virus infection. *Cell* **177**, 1566–1582 (2019).

78. Nielsen, S. C. A. et al. Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2. *Cell Host Microbe* **28**, 516–525 (2020).
79. Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. *Cell* **184**, 169–183 (2021).
80. Victoria, G. D. & Nussenzweig, M. C. Germinal centers. *Annu Rev. Immunol.* **30**, 429–457 (2012).
81. Maiese, A. et al. Autopsy findings in COVID-19-related deaths: a literature review. *Forensic Sci. Med. Pathol.* **17**, 279–296 (2020).
82. Deshmukh, V., Motwani, R., Kumar, A., Kumari, C. & Raza, K. Histopathological observations in COVID-19: a systematic review. *J. Clin. Pathol.* **74**, 76–83 (2021).
83. Diao, B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). *Front. Immunol.* **11**, 827 (2020).
84. Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J. Clin. Invest.* **130**, 2620–2629 (2020).
85. Lucas, C. et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature* **584**, 463–469 (2020).
86. Consiglio, C. R. et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. *Cell* **183**, 968–981 (2020).
87. Vella, L. et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared with adult and pediatric COVID-19. *Sci. Immunol.* **6**, eabf7570 (2021).
88. Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell* **183**, 158–168 (2020).
89. Zheng, H.-Y. et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. *Cell. Mol. Immunol.* **17**, 541–543 (2020).
90. Zheng, M. et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell. Mol. Immunol.* **17**, 533–535 (2020).
91. Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell* **181**, 1489–1501 (2020).
92. Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. *Nature* **587**, 270–274 (2020).
93. Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **584**, 457–462 (2020).
94. Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science* **370**, 89–94 (2020).
95. Weiskopf, D. et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. *Sci. Immunol.* **5**, eabd2071 (2020).
96. Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. *Immunity* **52**, 971–977 (2020).
97. Peng, Y. et al. Broad and strong memory CD4⁺ and CD8⁺ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat. Immunol.* **21**, 1336–1345 (2020).
98. Neidleman, J. et al. SARS-CoV-2-specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential. *Cell Rep. Med.* **1**, 100081 (2020).
99. Kared, H. et al. SARS-CoV-2-specific CD8⁺ T cell responses in convalescent COVID-19 individuals. *J. Clin. Invest.* **131**, e145476 (2021).
100. Meckiff, B. J. et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4⁺ T cells in COVID-19. *Cell* **183**, 1340–1353 (2020).
101. Kusanadi, A. et al. Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8⁺ T cells. *Sci. Immunol.* **6**, eabe4782 (2021).
102. Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. *Nat. Rev. Immunol.* **20**, 457–458 (2020).
103. Lipsitch, M., Grad, Y. H., Sette, A. & Crotty, S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. *Nat. Rev. Immunol.* **20**, 709–713 (2020).
104. Ferretti, A. P. et al. Unbiased screens show CD8⁺ T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2, most of which are not located in the spike protein. *Immunity* **53**, 1095–1107 (2020).
105. Lin, L. et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. *Nat. Biotechnol.* **33**, 610–616 (2015).
106. Bacher, P. et al. Low-Avidity CD4⁺ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. *Immunity* **53**, 1258–1271.e5 (2020).
107. Muus, C. et al. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. *Nat. Med.* **27**, 546–559 (2021).
108. Sze, S. et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. *EClinicalMedicine* **29**, 100630 (2020).
109. Benitez, J., Courtemanche, C. & Yelowitz, A. Racial and ethnic disparities in COVID-19: evidence from six large cities. *J. Econ. Race Policy* **3**, 243–261 (2020).
110. Kopel, J. et al. Racial and gender-based differences in COVID-19. *Front. Public Health* **8**, 418 (2020).
111. Gu, T. et al. Characteristics associated with racial/ethnic disparities in COVID-19 outcomes in an academic health care system. *JAMA Netw. Open* **3**, e2025197 (2020).
112. Bhopal, S. S. & Bhopal, R. Sex differential in COVID-19 mortality varies markedly by age. *Lancet* **396**, 532–533 (2020).
113. Starke, K. R. et al. The age-related risk of severe outcomes due to COVID-19 infection: a rapid review, meta-analysis, and meta-regression. *Int. J. Environ. Res. Public Health* **17**, 5974 (2020).
114. Ho, F. K. et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. *PLoS ONE* **15**, e0241824 (2020).
115. Pierce, C. A. et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Sci. Transl. Med.* **12**, eabd5487 (2020).
116. Weisberg, S. P. et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nat. Immunol.* **22**, 25–31 (2021).
117. Hobbs, C. V., Khaitan, A., Kirmse, B. M. & Borkowsky, W. COVID-19 in children: a review and parallels to other hyperinflammatory syndromes. *Front. Pediatr.* **8**, 593455 (2020).
118. Zarin, D. A. & Rosenfeld, S. Lack of harmonization of coronavirus disease ordinal scales. *Clin. Trials* **18**, 263–264 (2020).
119. Zheng, H. et al. Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity across viruses. *Immunity* **54**, 753–768 (2021).
120. Su, Y. et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. *Cell* **183**, 1479–1495 (2020).
121. Amezquita, R. A. et al. Orchestrating single-cell analysis with Bioconductor. *Nat. Methods* **17**, 137–145 (2020).
122. Stuart, T. et al. Comprehensive integration of single-cell data. *Cell* **177**, 1888–1902 (2019).
123. Regev, A. et al. The Human Cell Atlas. *eLife* **6**, e27041 (2017).
124. *Human Cell Atlas Data Portal* (accessed 17 February 2021); <https://data.humancellatlas.org/about>
125. Ballestar, E. et al. Single cell profiling of COVID-19 patients: an international data resource from multiple tissues. Preprint at *medRxiv* <https://doi.org/10.1101/2020.11.20.20227355> (2020).
126. Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587 (2021).
127. Bernardes, J. P. et al. Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19. *Immunity* **53**, 1296–1314 (2020).
128. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* **36**, 411–420 (2018).
129. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* **19**, 15 (2018).
130. Lake, B. B. et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. *Nat. Biotechnol.* **36**, 70–80 (2018).
131. Wen, W. et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. *Cell Discov.* **6**, 31 (2020).
132. Zhu, L. et al. Single-cell sequencing of peripheral mononuclear cells reveals distinct immune response landscapes of COVID-19 and influenza patients. *Immunity* **53**, 685–696 (2020).
133. Yu, K. et al. Dysregulated adaptive immune response contributes to severe COVID-19. *Cell Res.* **30**, 814–816 (2020).
134. Yao, C. et al. Cell-type-specific immune dysregulation in severely ill COVID-19 patients. *Cell Rep.* **34**, 108590 (2021).
135. Bost, P. et al. Deciphering the state of immune silence in fatal COVID-19 patients. *Nat. Commun.* **12**, 1428 (2021).
136. Combes, A. J. et al. Global absence and targeting of protective immune states in severe COVID-19. *Nature* **591**, 124–130 (2021).
137. Heming, M. et al. Neurological manifestations of COVID-19 feature T cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid. *Immunity* **54**, 164–175 (2021).
138. Varchetta, S. et al. Unique immunological profile in patients with COVID-19. *Cell. Mol. Immunol.* **18**, 604–612 (2020).
139. Osman, M. et al. Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. *Blood Adv.* **4**, 5035–5039 (2020).

Acknowledgements

We thank D.A. Nambi and G.K. Krenn for their help with building the data-visualization portal. R.G. was funded by the NIH Human Immunology Project Consortium (U19AI128914) and the Vaccine and Immunology Statistical Center (Bill and Melinda Gates Foundation, OPP1032317). E.W.N. was funded by the Fred Hutchinson Cancer Research Center New Development funds, the Andy Hill Endowment Distinguished

Researcher CARE fund and the NIH Human Immunology Project Consortium (U19AI128914). We also acknowledge the Scientific Computing Infrastructure at Fred Hutchinson funded by ORIP grant S10OD028685.

Author contributions

Y.T., E.W.N. and R.G. conceived the project. Y.T. and H.E.R.M. collected, processed and standardized the single-cell transcriptomic datasets. M.Z. built the visualization portal. Y.T., L.N.C., E.W.N. and R.G. wrote the manuscript. E.W.N. and R.G. supervised the project.

Competing interests

R.G. has received consulting income from Juno Therapeutics, Takeda, Infotech Soft, Celgene and Merck; has received research support from Janssen Pharmaceuticals and Juno Therapeutics; and declares ownership in Ozette Technologies and Modulus

Therapeutics. E.W.N. is a cofounder, advisor and shareholder of ImmunoScape; and is an advisor for Neogene Therapeutics and NanoString Technologies.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41587-021-01131-y>.

Correspondence should be addressed to Evan W. Newell or Raphael Gottardo.

Peer review information *Nature Biotechnology* thanks Catherine Blish, Roland Eils and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to claims in published maps and institutional affiliations.

© Springer Nature America, Inc. 2021